Enterprise Value
498.8M
Cash
328.7M
Avg Qtr Burn
-36.02M
Short % of Float
10.07%
Insider Ownership
28.73%
Institutional Own.
75.15%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Qinlock (ripretinib) (KIT & PDGFRA inhibitor) Details GIST (Gastrointestinal stromal tumors) (fourth-line) | Approved Quarterly sales | |
Vimseltinib (DCC-3014) (CSF1R inhibitor) Details Tenosynovial Giant Cell Tumors, Cancer | NDA Submission | |
Qinlock (Ripretinib) Details Gastrointestinal stromal tumors | Phase 3 Data readout | |
DCC-3116 (Inhibitor of ULK) + trametinib, sotorasib & binimetin Details Solid tumor/s, Cancer | Phase 1/2 Update | |
Vimseltinib (DCC-3014) (CSF1R inhibitor) Details Cancer, Tenosynovial Giant Cell Tumors | Phase 1/2 Update | |
DCC-3116 (Inhibitor of ULK)+encorafenib & cetuximab Details Solid tumor/s, Colorectal cancer , Cancer | Phase 1 Data readout | |
DCC-3116 (Inhibitor of ULK)+Qinlock Details Solid tumor/s, Gastrointestinal stromal tumors | Phase 1 Data readout | |
Rebastinib (TIE2 inhibitor) + Paclitaxel Details Solid tumor/s, Cancer | Failed Discontinued |